The FDA announced that MedWatch has updated its information on the potential drug interaction between Zyvox (linezolid; Pfizer) and serotonergic psychiatric medications. Not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with Zyvox. Most cases from the FDA’s Adverse Event Reporting System (AERS) of serotonin syndrome with Zyvox occurred in patients taking specific serotonergic psychiatric drugs, namely a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor. It is unclear at this time whether Zyvox administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk.
The FDA will update the public when new information is available.
Zyvox is indicated for the treatment of susceptible vancomycin-resistant E. faecium (VREF) infections, nosocomial and community-acquired pneumonia, complicated skin and skin structure infections (including diabetic foot infections) without osteomyelitis, uncomplicated skin and skin structure infections.
For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265479.htm.